Screening for liver cancer during transplant waiting list

Piñero, Federico; Marciano, Sebastián; Anders, Margarita; Orozco, Federico; Zerega, Alina; Cabrera, Carla Ramirez; Baña, Matías Tisi; Gil, O.; Andriani, Oscar; Santibañés, Eduardo de; McCormack, Lucas; Gadano, Adrián; Silva, Marcelo

doi:10.1097/meg.0000000000000272

Cited by 11 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the sensitivity was 33% and specificity was 99%. 54 These results are in line with a recent meta-analysis that showed a sensitivity of 45% for detection of early HCC with a specificity of 84%. 55 There is no large study analyzing the coverage of ultrasound screening for early detection of HCC, mainly in remote areas of Latin America.…”

Section: Screening For Hcc In Latin Americasupporting

confidence: 87%

Epidemiology of Liver Cancer in Latin America: Current and Future Trends

et al. 2019

View full text Add to dashboard Cite

Over 38,000 cases of hepatocellular carcinoma (HCC) are estimated to occur in Latin America annually. The region is characterized by sociocultural heterogeneity and economic disparities, which impose barriers in addressing this major health issue. A significant proportion of patients are still diagnosed in the later stages of the disease, although efforts to implement effective screening programs have been reported by referral centers. While viral hepatitis remains the predominant etiology of liver disease among HCC cases in Latin America, a high prevalence of fatty liver disease in the region is a matter of concern, reflecting the current scenario in many Western countries. In addition, other risk factors such as alcohol, aflatoxin, and early-onset HCC in hepatitis B virus infection contribute to the burden of HCC in Latin America. Interventions to increase screening coverage, expand healthcare access, and implement continuing medical training are key challenges to be overcome.

show abstract

Section: Screening For Hcc In Latin Americasupporting

confidence: 87%

Epidemiology of Liver Cancer in Latin America: Current and Future Trends

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Furthermore, MELD exception points approval rates were similar for HCV and non‐HCV etiologies in a recent South American liver transplantation survey (unpublished data). Thus, we believe this conservative bias does not affect the validity of our results …”

Section: Discussionmentioning

confidence: 76%

“…If MELD exception points for HCC were approved, patients were listed with 22 points—plus 1 point every 3 months on the waiting list—until transplantation. It is estimated that HCC MELD exception point approval rates reach 66% in Argentina …”

Section: Methodsmentioning

confidence: 99%

Trends in liver transplantation for hepatitis C in a country with reduced access to direct‐acting antiviral agents

Dirchwolf

Marciano

Giunta

et al. 2018

Clinical Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nine studies had applicability concerns about patient selection given inclusion of patients with advanced fibrosis but not cirrhosis. 16, 21–24, 30, 33, 37, 44, Most studies used standard reference tests to confirm HCC diagnosis, including CT, MRI, and biopsy; however, 10 studies used AFP > 400 ng/mL, so reference tests were not independent of the surveillance tests. Further, elevated AFP is no longer recommended for diagnosis by AASLD guidelines for HCC diagnosis given imperfect specificity.…”

Section: Resultsmentioning

confidence: 99%